Search

everythinglearnresearchcommunity

for

Search:↓

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

Infliximab successfully treated a severe hair loss case in Sri Lanka.

The study created special nanoparticles that effectively deliver an anti-inflammatory drug to treat skin inflammation in psoriasis.

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

Baricitinib is effective and safe for treating alopecia areata.

Enhancing immune response can improve cancer treatment effectiveness.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.

Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Omalizumab may cause hair loss.

Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.

The new gel combining minoxidil and tofacitinib effectively treats alopecia areata by promoting hair growth and reducing inflammation.

Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Oral baricitinib is effective and safe for treating alopecia areata.

Biosimilars lower costs but don't significantly improve access.

Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

Nivolumab can cause hair loss as a rare side effect.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.